Alteration of the methylation status of tumor-promoting genes decreases prostate cancer cell invasiveness and tumorigenesis in vitro and in vivo

Cancer Research

Volumn 66, Issue 18, 2006, Pages 9202-9210

  Shukeir, Nicholas ^a   Pakneshan, Pouya ^a   Chen, Gaoping ^a   Szyf, Moshe ^a   Rabbani, Shafaat A ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; BISULFITE; DRUG VEHICLE; GELATINASE A; GENOMIC DNA; GLUTATHIONE TRANSFERASE P1; OLIGONUCLEOTIDE; PLASMINOGEN ACTIVATOR; S ADENOSYLMETHIONINE; VASCULOTROPIN;

ARTICLE; CANCER CELL; CARCINOGENESIS; CELL INVASION; DNA FLANKING REGION; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INOCULATION; MALE; METHYLATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; SEQUENCE ANALYSIS;

ANIMALS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; DNA METHYLATION; DNA-BINDING PROTEINS; DOWN-REGULATION; GENE THERAPY; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MICE; MICE, INBRED BALB C; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; OLIGONUCLEOTIDES, ANTISENSE; PLASMINOGEN ACTIVATORS; PROSTATIC NEOPLASMS; RNA, MESSENGER; S-ADENOSYLMETHIONINE; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33749483782     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-1954     Document Type: Article

References (44)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-30.
2. Kawakami J, Cowan JE, Elkin EP, et al. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Cancer 2006;106:1708-14.
3. Kirby R. Management of clinically localized prostate cancer by radical prostatectomy followed by watchful waiting. Nat Clin Pract Urol 2005;2:298-303.
4. Salesi N, Carlini P, Ruggeri EM, et al. Prostate cancer: the role of hormonal therapy. J Exp Clin Cancer Res 2005;24:175-80.
5. Arnold JT, Isaacs JT. Mechanisms involved in the progression of androgen-independent prostate cancers: it is not only the cancer cell's fault. Endocr Relat Cancer 2002;9:61-73.
6. Clines GA, Guise TA. Mechanisms and treatment for bone metastases. Clin Adv Hematol Oncol 2004;2:295-301.
7. Fidler IJ. Understanding bone metastases: the key to the effective treatment of prostate cancer. Clin Adv Hematol Oncol 2003;1:278-9.
8. Mollabashy A, Scarborough M. The mechanism of metastasis. Orthop Clin North Am 2000;31:529-35.
9. Jennbacken K, Vallbo C, Wang W, Damber JE. Expression of vascular endothelial growth factor C (VEGF-C) and VEGF receptor-3 in human prostate cancer is associated with regional lymph node metastasis. Prostate 2005;65:110-6.
10. Kambhampati S, Ray G, Sengupta K, et al. Growth factors involved in prostate carcinogenesis. Front Biosci 2005;10:1355-67.
11. Brehmer B, Biesterfeld S, Jakse G. Expression of matrix metalloproteinases (MMP-2 and -9) and their inhibitors (TIMP-1 and -2) in prostate cancer tissue. Prostate Cancer Prostatic Dis 2003;6:217-22.
12. Stamenkovic I. Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol 2000;10:415-33.
13. Zhang L, Shi J, Feng J, et al. Type IV collagenase (matrix metalloproteinase-2 and -9) in prostate cancer. Prostate Cancer Prostatic Dis 2004;7:327-32.
14. Rabbani SA. Metalloproteases and urokinase in angiogenesis and tumor progression. In Vivo 1998;12:135-42.
15. Rabbani SA, Mazar AP. The role of the plasminogen activation system in angiogenesis and metastasis. Surg Oncol Clin N Am 2001;10:393-415.
16. Rabbani SA, Xing RH. Role of urokinase (uPA) and its receptor (uPAR) in invasion and metastasis of hormone-dependent malignancies. Int J Oncol 1998;12:911-20.
17. Esteller M. DNA methylation and cancer therapy: new developments and expectations. Curr Opin Oncol 2005;17:55-60.
18. Strathdee G, Brown R. Epigenetic cancer therapies: DNA methyltransferase inhibitors. Expert Opin Investig Drugs 2002;11:747-54.
19. Kalebic T. Epigenetic transitions: towards therapeutic targets. Expert Opin Ther Targets 2003;7:693-9.
20. Brown R, Strathdee G. Epigenomics and epigenetic therapy of cancer. Trends Mol Med 2002;8:S43-8.
21. Szyf M. Targeting DNA methylation in cancer. Ageing Res Rev 2003;2:299-328.
22. Razin A, Riggs AD. DNA methylation and gene function. Science 1980;210:604-10.
23. Baylin SB, Esteller M, Rountree MB, et al. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet 2001;10:687-92.
24. Ehrlich M. DNA methylation in cancer: too much, but also too little. Oncogene 2002;21:5400-13.
25. Pakneshan P, Xing RH, Rabbani SA. Methylation status of uPA promoter as a molecular mechanism regulating prostate cancer invasion and growth in vitro and in vivo. FASEB J 2003;17:1081-8.
26. Detich N, Hamm S, Just G, Knox JD, Szyf M. The methyl donor 5-adenosylmethionine inhibits active demethylation of DNA: a candidate novel mechanism for the pharmacological effects of S-adenosylmethionine. J Biol Chem 2003;278:20812-20.
27. Chiang PK, Gordon RK, Tal J, et al. S-adenosylmethionine and methylation. FASEB J 1996;10:471-80.
28. Pakneshan P, Szyf M, Farias-Eisner R, Rabbani SA. Reversal of the hypomethylation status of urokinase (uPA) promoter blocks breast cancer growth and metastasis. J Biol Chem 2004;279:31735-44.
29. Patra SK, Patra A, Zhao H, Dahiya R. DNA methyltransferase and demethylase in human prostate cancer. Mol Carcinog 2002;33:163-71.
30. Slack A, Bovenzi V, Bigey P, et al. Antisense MBD2 gene therapy inhibits tumorigenesis. J Gene Med 2002;4:381-9.
31. Sansom OJ, Berger J, Bishop SM, et al. Deficiency of Mbd2 suppresses intestinal tumorigenesis. Nat Genet 2003;34:145-7.
32. Berger J, Bird A. Role of MBD2 in gene regulation and tumorigenesis. Biochem Soc Trans 2005;33:1537-40.
33. Campbell PM, Bovenzi V, Szyf M. Methylated DNA-binding protein 2 antisense inhibitors suppress tumourigenesis of human cancer cell lines in vitro and in vivo. Carcinogenesis 2004;25:499-507.
34. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 1996;93:9821-6.
35. Chen G, Shukeir N, Potti A, et al. Up-regulation of Wnt-1 and β-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications. Cancer 2004;101:1345-56.
36. Szyf M. The role of DNA methyltransferase 1 in growth control. Front Biosci 2001;6:D599-609.
37. MacLeod AR, Szyf M. Expression of antisense to DNA methyltransferase mRNA induces DNA demethylation and inhibits tumorigenesis. J Biol Chem 1995;270:8037-43.
38. Ramchandani S, MacLeod AR, Pinard M, von Hofe E, Szyf M. Inhibition of tumorigenesis by a cytosine-DNA, methyltransferase, antisense oligodeoxynucleotide. Proc Natl Acad Sci U S A 1997;94:684-9.
39. McCabe MT, Low JA, Daignault S, et al. Inhibition of DNA methyltransferase activity prevents tumorigenesis in a mouse model of prostate cancer. Cancer Res 2006;66:385-92.
40. Sato N, Maehara N, Su GH, Goggins M. Effects of 5-aza-2′- deoxycytidine on matrix metalloproteinase expression and pancreatic cancer cell invasiveness. J Natl Cancer Inst 2003;95:327-30.
41. Schmutte C, Fishel R. Genomic instability: first step to carcinogenesis. Anticancer Res 1999;19:4665-96.
42. Ng HH, Zhang Y, Hendrich B, et al. MBD2 is a transcriptional repressor belonging to the MeCP1 histone deacetylase complex. Nat Genet 1999;23:58-61.
43. Bhattacharya SK, Ramchandani S, Cervoni N, Szyf M. A mammalian protein with specific demethylase activity for mCpG DNA. Nature 1999;397:579-83.
44. Detich N, Theberge J, Szyf M. Promoter-specific activation and demethylation by MBD2/demethylase. J Biol Chem 2002;277:35791-4.